HTFL Heartflow, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1464521 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY47.4%
TTM net income YoY37.0%
TTM EPS YoY106.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin81.8%
Operating margin-33.1%
Net margin-33.1%
FCF margin-23.5%
EBITDA margin-30.8%
Returns
ROE-29.4%
ROA-22.0%
ROIC (approx.)-58.2%
Asset turnover0.66x
Leverage & solvency
Liabilities / assets20.5%
Debt / equity0.00x
Current ratio4.41x
Interest coverage-4,937.50x
Cash quality & payout
Operating cash flow / net income0.62x
Accruals ratio-8.4%
Payout ratio—
Capex / revenue3.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | $176.03M | $125.81M | $87.17M |
| Cost of revenue | $40.84M | $31.36M | $29.12M |
| Gross profit | $135.20M | $94.45M | $58.05M |
| R&D expense | $64.92M | $43.52M | $35.85M |
| SG&A expense | $134.34M | $112.15M | $95.11M |
| Operating income | -$64.07M | -$61.22M | -$72.91M |
| Interest expense | $15.17M | $22.77M | $24.69M |
| Pretax income | -$116.87M | -$96.37M | -$95.11M |
| Income tax | -$76,000 | $53,000 | $547,000 |
| Net income | -$116.79M | -$96.43M | -$95.66M |
| EBITDA | -$58.63M | -$55.86M | -$68.17M |
| EPS (basic) | -3.17 | -17.98 | -25.32 |
| EPS (diluted) | -3.17 | -17.98 | -25.32 |
| Weighted avg. shares (diluted) | 36.85M | 5.36M | 4.89M |
| Balance sheet | |||
| Cash & equivalents | $44.78M | $55.84M | $122.77M |
| Short-term investments | $132.01M | — | — |
| Receivables | $29.34M | $24.64M | — |
| Current assets | $220.20M | $82.29M | — |
| PP&E, net | $8.59M | $8.92M | — |
| Total assets | $359.45M | $118.70M | — |
| Current liabilities | $42.37M | $33.60M | — |
| Total liabilities | $58.80M | $209.62M | — |
| Shareholders' equity | $300.65M | -$859.48M | -$777.56M |
| Shares outstanding | 85.28M | 6.12M | — |
| Cash flow statement | |||
| Operating cash flow | -$54.02M | -$69.00M | -$76.43M |
| Capital expenditure | $5.03M | $4.36M | $6.11M |
| Free cash flow | -$59.05M | -$73.36M | -$82.54M |
| Investing cash flow | -$238.57M | -$4.36M | -$6.11M |
| Financing cash flow | $286.04M | $2.24M | $169.32M |
| Depreciation & amortization | $5.44M | $5.36M | $4.74M |
| Stock-based compensation | $13.96M | $10.21M | $11.87M |
| Share buybacks | — | — | $228,000 |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.